Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike

Jan 20 2014

• By Cathy Dombrowski

Related Content

Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials

Jan 21 2013

Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing

Feb 12 2007

Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain

Apr 19 2012

Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

Jan 20 2014

CDC’s Antibiotic-Resistance Battle Plan Emphasizes Preserving Current Drugs

Sep 17 2013

Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity

Feb 18 2008

Related Companies

GSK plc

Melinta Therapeutics, Inc.

Sanofi

Cubist Pharmaceuticals, Inc.

Additional Topics

United States Regulation Drug Approval Standards BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window